AstraZeneca says ALXN1840 phase III trial in Wilson disease meets primary endpoint
ALXN1840, a potential new once-daily, oral medicine, demonstrated three times greater copper mobilisation than standard treatments
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 20 of 55
AstraZeneca’s Forxiga approved in Japan for chronic kidney disease
A phase III trial showed that Forxiga reduced the risk of worsening of renal function, onset of end-stage kidney disease or risk of cardiovascular or renal death by 39%
NHS preparing to vaccinate 12-15 year olds - reports
Reports have suggested the plan is to start vaccinations ahead of the September return to school.
AstraZeneca stops phase III trial for ALS drug
The trial of the group's Ultomiris treatment was halted due to lack of efficacy
AstraZeneca says antibody drug phase III trial shows significant reduction in symptomatic Covid-19
The company's AZD7442 drug reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo
Study shows vaccines work but fails to quell Delta variant concerns
“Both of these vaccines, at two doses, are still doing really well against Delta"
Are AstraZeneca shares worth buying? Read what this big hitting City broker has to say before making your call
“We see Astra’s sector discount unwinding, as the Alexion acquisition demonstrates continued strong top-line growth, coupled with significant operating margin expansion and increased free cash flow generation,” JP Morgan Cazenove said in it
AstraZeneca offers sector-leading growth at reasonable price, says Morgan Stanley
The investment bank resumed coverage with an ‘overweight’ recommendation and a 9,800p target price
AstraZeneca receives EU approval for chronic kidney disease drug
The group also announced positive final-stage trial results for Enhertu on breast cancer patients
Government wants UK investment 'big bang' to compete with US giants
It’s time we recognised the quality that other countries see in the UK, and back ourselves by investing more money"
AstraZeneca receives US approval for lupus drug Saphnelo
Trial patients experienced a reduction in organ damage and needed fewer oral corticosteroids, which can cause side effects
AstraZeneca questioning future Covid-19 vaccine involvement
"Is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years/"
AstraZeneca eyes big jump in revenue after Alexion acquisition
In the first half of the year, the COVID-19 vaccine delivered sales twice the consensus view
AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids
The group said the efficacy and safety of Ultomiris in children and teens are consistent with what has been demonstrated in adults.
AstraZeneca receives green light for small cell lung cancer treatment in China
The approval was based on positive results from a phase III trial where Imfinzi showed improvement compared to chemotherapy alone
AstraZeneca and FibroGen face FDA rejection of anaemia drug
Before the committee’s meeting, the FDA issued a briefing document that said the drug’s safety in CKD patients was the main issue
AstraZeneca gets final go-ahead for £27.5bn Alexion acquisition
Rare diseases "represent a high-growth opportunity with rapid innovation and significant unmet medical needs", the company said
Archive
Today's Market View - Pure Gold Mining and more...
Arkle Resources* (AIM:ARK) – Drilling at Tombreen encounters gold in the first four holes of the current campaign Atalaya Mining (AIM:ATYM) – Mineral reserves and resources update for Cerro Colorado and San Dionisio Petra Diamonds (LON:PDL)
AstraZeneca receives US priority review for asthma candidate
A final decision is expected in the first quarter of 2022
AstraZeneca is a key pick, but which other stocks are on this top bank's 'buy' list?
UBS has prepared a list of European stocks ahead of results season where it expects the numbers to exceed expectations